June 26, 2012 – Vancouver, British Columbia – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB:REPCF) Chief Scientific Officer, Dr. Kevin McElwee, presented results from the Company’s TS001-2009 first-in-man clinical study at the 16th meeting of the European Hair Research Society in Barcelona, Spain this past week.
Dr. McElwee’s presentation included a brief review of preclinical research data, an examination of the production development process, and an interim analysis of six-month post-injection data. All findings from this interim analysis will be incorporated into the regulatory filings presently being developed for European regulators for the initiation of a Phase II dose-ranging trial. The preliminary plans for the Phase II trial were also presented in Barcelona.
The European Hair Research Society (EHRS) is an independent, non-profit organization dedicated topromoting the research of hair biology and hair disease in Europe. Their international membership includes scientists, dermatologists and professionals working in academia, industry and government. The EHRS supports and organizes meetings throughout Europe, dedicated to the presentation of new research findings, exchange of information, education of its members and the advancement of science.
About RepliCel Life Sciences Inc.
The Company has developed RepliCel™, a patented natural hair cell replication technology that has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, initiates natural hair regeneration. The Company is currently conducting first-in-man clinical trials. Additional information on RepliCel is available at www.replicel.com.
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements, including that the Company will complete a Phase IIb clinical trial and that RepliCel™ has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking statements. These risks and uncertainties include: whether the Company can obtain regulatory approval for its planned Phase IIb clinical trial; that negative results may result from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital to carry out its planned activities; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2011, and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.